RdC regimen
WikiDoc Resources for RdC regimen |
Articles |
---|
Most recent articles on RdC regimen Most cited articles on RdC regimen |
Media |
Powerpoint slides on RdC regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on RdC regimen at Clinical Trials.gov Clinical Trials on RdC regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on RdC regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on RdC regimen Discussion groups on RdC regimen Patient Handouts on RdC regimen Directions to Hospitals Treating RdC regimen Risk calculators and risk factors for RdC regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for RdC regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
RdC regimen refers to a regimen consisting of Lenalidomide (Revlimid), dexamethasone, Cyclophosphamide used to treat AL amyloidosis.[1]
Regimen
RRevlimid (Lenalidomide)
ddexamethasone
CCyclophosphamide
Indications
References
- ↑ 1.0 1.1 Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I; et al. (2012). "A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis". Blood. 119 (23): 5384–90. doi:10.1182/blood-2011-12-396903. PMID 22517904.